Clinical Trial Update: Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of canagliflozin (TA-7284) in patients with diabetic nephropathy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy

Drugs mentioned

• Canagliflozin (canagliflozin)

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Diabetic Nephropathy | Phase 3 | Status: COMPLETED | Results posted: 2024-07-15